Preventive or therapeutic agent for hydrocephalus and pharmaceutical composition for preventing or treating hydrocephalus

A compound promoting AQP4 function addresses the lack of effective medical treatments for hydrocephalus by improving cerebrospinal fluid dynamics, providing a promising radical treatment for non-obstructive forms.

JP7593648B2Active Publication Date: 2024-12-03NIIGATA UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021562592
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-03
Filing Date
2020-11-25
Publication Date
2024-12-03
Estimated Expiration
2040-11-25

AI Technical Summary

Technical Problem

Current treatments for hydrocephalus, particularly non-obstructive forms like idiopathic normal pressure hydrocephalus, lack effective medical therapies beyond invasive surgical shunts, which are risky and uncertain in efficacy.

Method used

A prophylactic or therapeutic agent containing a compound represented by general formula (1) or its pharmaceutically acceptable salt, which promotes the function of aquaporin 4 (AQP4) to improve cerebrospinal fluid dynamics, administered orally or parenterally.

Benefits of technology

The agent effectively reduces hydrocephalus symptoms by enhancing AQP4 function, offering a radical medical treatment option for hydrocephalus, particularly non-obstructive types, with demonstrated improvements in ventricle volume, cerebral edema, and neurological signs in preclinical models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593648000011
    Figure 0007593648000011
  • Figure 0007593648000012
    Figure 0007593648000012
  • Figure 0007593648000013
    Figure 0007593648000013
Patent Text Reader

Abstract

This drug for preventing or treating hydrocephalus contains, as the active ingredient, a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof. (In the formula, R is a saturated aliphatic hydrocarbon group, an alicyclic heterocycle group, an aromatic hydrocarbon group, or an aromatic heterocycle group that has 1-10 carbons and that is optionally substituted.)
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a preventive or therapeutic agent for hydrocephalus and a pharmaceutical composition for the prevention or treatment of hydrocephalus. This application claims priority based on Japanese Patent Application No. 2019-218835, filed on December 3, 2019, the contents of which are incorporated herein by reference. [Background technology]

[0002] Hydrocephalus is a pathological condition that is accompanied by ventricular expansion and cerebral edema in the brain parenchyma due to circulatory disorders of intracranial cerebrospinal fluid. Hydrocephalus is divided into obstructive hydrocephalus, in which the circulatory pathway is blocked, and nonobstructive hydrocephalus, in which the cerebrospinal fluid absorption pathway is thought to be widely damaged, but the mechanism is currently unknown. The former is accompanied by cerebral hemorrhage or brain trauma, and the disorder appears suddenly, and is life-threatening. The latter is represented by idiopathic normal pressure hydrocephalus, which is one of the causes of cognitive impairment in elderly people. Current treatments for both types of hydrocephalus are centered on surgical therapy (shunt surgery) in which a catheter is inserted into the ventricles to allow cerebrospinal fluid to escape from the skull. However, the treatment results are inconsistent, and in particular in nonobstructive hydrocephalus, there are many cases where surgical treatment does not improve the condition. For this reason, there is an urgent need to develop a medical cure that will alleviate the symptoms.

[0003] Meanwhile, aquaporin, a water transport protein, was discovered in 1993, and since aquaporin 4 is abundant in the brain, it is predicted that aquaporin 4 (AQP4) is involved in water dynamics in the brain. In recent years, it has been confirmed that AQP4-deficient mice exhibit severe obstructive hydrocephalus-like symptoms, and ventricular enlargement and neurological symptoms are more severe than those of normal mice (see, for example, Non-Patent Document 1). Although it has become clear that AQP4 is involved in the development of hydrocephalus, it remains unclear whether AQP4 has a protective effect or a harmful effect (see, for example, Non-Patent Document 2).

[0004] The inventors have previously developed compounds that have the effect of directly promoting the function of aquaporin 4 (see, for example, Patent Document 1). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2017 / 150704 [Non-patent literature]

[0006] [Non-Patent Document 1] Feng X et al., “Sporadic Obstructive Hydrocephalus in Aqp4 Null Mice.”, J Neurosci Res., Vol. 87, Issue 5, pp. 1150-1155, 2009. [Non-Patent Document 2] Mader S et al., Review, “Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease.”, Cells, Vol. 8, Issue 2, 90; https: / / doi.org / 10.3390 / cells8020090, 2019. Summary of the Invention [Problem to be solved by the invention]

[0007] Currently, the mainstream treatment for hydrocephalus is the above-mentioned surgical shunt procedure, but it is invasive, carries the risk of infection, and its therapeutic effectiveness is uncertain. In addition, there is no clinically effective drug therapy for hydrocephalus. Therefore, there is a strong demand for the development of a drug that can be used as a medical cure.

[0008] The present invention has been made in view of the above circumstances, and provides a novel drug for preventing or treating hydrocephalus. [Means for solving the problem]

[0009] That is, the present invention includes the following aspects. The preventive or therapeutic agent for normal pressure hydrocephalus according to the first aspect of the present invention comprises a compound represented by the following general formula (1) or a pharma- ceutical acceptable salt thereof as an active ingredient.

[0010] [ka]

[0011] (In the formula, R is a saturated aliphatic hydrocarbon group, an alicyclic heterocyclic group, an aromatic hydrocarbon group, or an aromatic heterocyclic group, which may have a substituent having 1 to 10 carbon atoms.)

[0012] The R may be a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, an n-pentyl group, an isopentyl group, an n-hexyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a phenyl group, a 4-chlorophenyl group, a 2-pyrrolidinyl group, a 3-pyrrolidinyl group, a 2-tetrahydrofuranyl group, a 3-tetrahydrofuranyl group, a 2-pyrrolyl group, a 3-pyrrolyl group, a 2-furanyl group, or a 3-furanyl group. In adults, it may be administered orally in an amount of from 0.1 to 4 g per day, or parenterally in an amount of from 0.05 to 3 g per day.

[0013] A pharmaceutical composition for preventing or treating normal pressure hydrocephalus according to a second aspect of the present invention comprises the agent for preventing or treating normal pressure hydrocephalus according to the first aspect and a pharma- ceutically acceptable carrier. Effect of the Invention

[0014] The preventive or therapeutic drug for hydrocephalus and the pharmaceutical composition for preventing or treating hydrocephalus according to the above-mentioned aspects can improve the symptoms of hydrocephalus, and are useful for medical radical treatment. [Brief description of the drawings]

[0015] [Figure 1]1 is a graph showing neurological scores in a TGN-073 administration group and a saline administration group in Example 1. [Diagram 2] 1 shows T2-weighted images of preclinical high-field magnetic resonance imaging in the TGN-073-administered group and the saline-administered group in Example 1. [Diagram 3] 1 shows the results of measuring the volumes of the ventricles and cerebral edema area in the TGN-073 administration group and the saline administration group in Example 1. [Figure 4] 1 shows the results of measuring cerebral blood flow in the cortex in a TGN-073 administration group and a saline administration group in Example 1. [Diagram 5] 1 shows the results of measuring cerebral edema in white matter in a TGN-073 administration group and a saline administration group in Example 1. [Figure 6A] 1 shows the results of measuring cortical neuronal density in a TGN-073-administered group and a saline-administered group in Example 1. [Figure 6B] 1 shows the results of measuring neuronal density in white matter in a TGN-073-administered group and a saline-administered group in Example 1. [Figure 7A] This shows T1-weighted images of preclinical high-field magnetic resonance imaging in the TGN-073 administration group and the saline administration group in Example 2. The time on the vertical axis indicates the elapsed time from the administration of gadopentetate dimeglumine (GD), which is a non-ionic MRI contrast agent. [Figure 7B] 7B is a graph showing the amount and rate of GD inflow into the brain parenchyma, created based on the image of FIG. 7A. [Figure 8A] 13 shows free water content calculation images from preclinical high-field magnetic resonance imaging in the TGN-073 administration group and the saline administration group in Example 3. [Figure 8B] 1 shows the results of measuring the amount of free water in the cerebral white matter in the TGN-073 administration group and the saline administration group in Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] <Aquaporin 4 (AQP4)> In general, "aquaporin 4 (AQP4)" is a member of the aquaporin family with extremely high water selectivity, and is the main AQP involved in water transport in the brain. AQP4 is also abundant in the brain, especially in the end-feet membranes of astrocytes that contact the basement membrane. In this specification, "promotion of AQP4 function" means promotion of water transport via AQP4. Promotion of water transport via AQP4 can promote the flow of cerebrospinal fluid (CSF) in the ventricles and the excretion function by the glymphatic system.

[0017] <Hydrocephalus> In general, "hydrocephalus" is a pathological condition accompanied by ventricular expansion and cerebral edema of the brain parenchyma due to circulatory disorders of cerebrospinal fluid in the skull. Hydrocephalus is divided into obstructive hydrocephalus, in which the circulatory pathway is blocked, and nonobstructive hydrocephalus, in which the cerebrospinal fluid absorption pathway is thought to be widely damaged, but the mechanism is currently unknown. In obstructive hydrocephalus, the circulatory pathway of cerebrospinal fluid is blocked by lesions such as brain tumors, causing high intracranial pressure, resulting in symptoms such as headache, vomiting, and impaired consciousness. These symptoms may be acutely aggravated, so care must be taken. On the other hand, in nonobstructive hydrocephalus, although ventricular expansion is observed, intracranial pressure is often only slightly elevated or maintained within the normal range, resulting in symptoms such as gait disturbance, dementia, and urinary incontinence. Hydrocephalus in which intracranial pressure is only slightly elevated or maintained within the normal range is also called normal pressure hydrocephalus. Normal pressure hydrocephalus is classified into "secondary normal pressure hydrocephalus (sNPH)" and "idiopathic normal pressure hydrocephalus (iNPH)." sNPH is when it occurs secondarily due to subarachnoid hemorrhage or head trauma, while iNPH is when it occurs in elderly people with no identified pre-existing disease or cause. The preventive or therapeutic drug for hydrocephalus of this embodiment can be applied to all of the above types of hydrocephalus, but is particularly suitable for non-obstructive hydrocephalus, and particularly suitable for idiopathic normal pressure hydrocephalus.

[0018] <Preventive or therapeutic drugs for hydrocephalus> The preventive or therapeutic drug for hydrocephalus (prophylactic or therapeutic drug) of this embodiment contains a compound represented by the following general formula (1) (hereinafter, may be referred to as "compound (1)") or a pharma- ceutically acceptable salt thereof as an active ingredient. In this specification, "containing as an active ingredient" means containing a therapeutically effective amount of compound (1). In addition, "therapeutically effective amount" means an amount of compound (1), or a combination of compound (1) and one or more active agents, that induces a biological or medical effect or response desired by a physician, clinician, veterinarian, researcher, or other appropriate professional when administered according to a desired treatment regimen. A preferred therapeutically effective amount is an amount that improves the symptoms of hydrocephalus. In addition, "therapeutically effective amount" includes a prophylactically effective amount, i.e., an amount suitable for preventing a disease state.

[0019] [ka]

[0020] (In the formula, R is a saturated aliphatic hydrocarbon group, an alicyclic heterocyclic group, an aromatic hydrocarbon group, or an aromatic heterocyclic group, which may have a substituent having 1 to 10 carbon atoms.)

[0021] According to the preventive or therapeutic drug for hydrocephalus of this embodiment, the symptoms of hydrocephalus can be improved, and it is useful as a medical radical treatment.

[0022] As shown in the Examples described later, the inventors administered compound (1) developed in Patent Document 1 to an existing hydrocephalus model mouse and found that the symptoms of hydrocephalus were improved by promoting the function of AQP4, leading to the completion of the present invention. Since there has been no clinically effective pharmacological treatment for hydrocephalus to date, the prophylactic or therapeutic drug for hydrocephalus of this embodiment is a drug that can be the world's first medical cure.

[0023] <Compound (1)> Compound (1) is a compound having a 2-sulfonamide-3-benzyloxypyridine skeleton, and binds directly to AQP4.

[0024] [ka]

[0025] (In the formula, R is a saturated aliphatic hydrocarbon group, an alicyclic heterocyclic group, an aromatic hydrocarbon group, or an aromatic heterocyclic group, which may have a substituent having 1 to 10 carbon atoms.)

[0026] [R] The saturated aliphatic hydrocarbon group (alkyl group) in R, which may have a substituent having 1 to 10 carbon atoms, may be linear, branched, or cyclic, and if cyclic, may be monocyclic or polycyclic. The saturated aliphatic hydrocarbon group preferably has a carbon number of 1 to 10, more preferably 1 to 8, even more preferably 1 to 6, and particularly preferably 1 to 4.

[0027] The linear saturated aliphatic hydrocarbon group (alkyl group) preferably has 1 or more and 10 or less carbon atoms, and examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an n-pentyl group, an n-hexyl group, an n-heptyl group, an n-octyl group, a nonyl group, and a decyl group. The linear alkyl group preferably has 1 or more and 10 or less carbon atoms, more preferably 1 or more and 8 or less carbon atoms, further preferably 1 or more and 6 or less carbon atoms, and particularly preferably 1 or more and 4 or less carbon atoms.

[0028] The branched saturated aliphatic hydrocarbon group (alkyl group) preferably has 3 or more and 10 or less carbon atoms, and examples thereof include an isopropyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a 1-methylbutyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 2,2-dimethylbutyl group, a 2,3-dimethylbutyl group, a 2-methylhexyl group, a 3-methylhexyl group, a 2,2-dimethylpentyl group, a 2,3-dimethylpentyl group, a 2,4-dimethylpentyl group, a 3,3-dimethylpentyl group, a 3-ethylpentyl group, a 2,2,3-trimethylbutyl group, an isooctyl group, and a 2-ethylhexyl group. The branched alkyl group preferably has 3 or more and 10 or less carbon atoms, more preferably 3 or more and 8 or less carbon atoms, further preferably 3 or more and 6 or less carbon atoms, and particularly preferably 3 or more and 4 or less carbon atoms.

[0029] More specifically, the linear or branched alkyl group in R is preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, an n-pentyl group, an isopentyl group, or an n-hexyl group.

[0030] The cyclic saturated aliphatic hydrocarbon group (cycloalkyl group) preferably has 3 to 10 carbon atoms, and examples of the cycloalkyl group include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, cyclononyl group, cyclodecyl group, norbornyl group, isobornyl group, 1-adamantyl group, 2-adamantyl group, and tricyclodecyl group. Furthermore, examples of the cycloalkyl group in which one or more hydrogen atoms are substituted with a halogen atom, a hydroxyl group, or a linear, branched, or cyclic alkyl group include those. Here, examples of the halogen atom that substitutes the hydrogen atom include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. Examples of the linear, branched, or cyclic saturated aliphatic hydrocarbon group that substitutes the hydrogen atom include those exemplified above as the alkyl group in R.

[0031] The cycloalkyl group is preferably monocyclic. The cycloalkyl group more preferably has 3 to 10 carbon atoms, more preferably 3 to 8 carbon atoms, and even more preferably 3 to 6 carbon atoms.

[0032] More specifically, the cycloalkyl group in R is preferably a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.

[0033] The alicyclic heterocyclic group which may have a substituent in R is composed of carbon and other elements (for example, nitrogen, oxygen, sulfur, etc.) The alicyclic heterocyclic group may be either monocyclic or polycyclic.

[0034] Examples of the alicyclic heterocyclic group include a nitrogen-containing alicyclic heterocyclic group, an oxygen-containing alicyclic heterocyclic group, a sulfur-containing alicyclic heterocyclic group, a nitrogen- and oxygen-containing alicyclic heterocyclic group, a nitrogen- and sulfur-containing alicyclic heterocyclic group, etc. Examples of the nitrogen-containing alicyclic heterocyclic group include an ethyleneimino group, an azacyclobutyl group, a pyrrolidinyl group, a piperidyl group, a piperidino group, a piperazinyl group, a hexamethyleneimino group, a heptamethyleneimino group, an octamethyleneimino group, a nonamethyleneimino group, a 1,3,5,7-tetraazaadamantyl group, etc. Examples of oxygen-containing alicyclic heterocyclic groups include epoxy groups, trimethylene oxide groups, tetrahydrofuranyl groups, tetrahydropyranyl groups, hexamethylene oxide groups, heptamethylene oxide groups, octamethylene oxide groups, nonamethylene oxide groups, and 2,4,6,8,9,10-hexaoxaadamantyl groups. Examples of sulfur-containing alicyclic heterocyclic groups include ethylene sulfide groups, trimethylene sulfide groups, tetrahydrothienyl groups, tetrahydrothiopyranyl groups, hexamethylene sulfide groups, heptamethylene sulfide groups, octamethylene sulfide groups, nonamethylene sulfide groups, and 2,4,6,8,9,10-hexathiaadamantyl groups. Examples of nitrogen- and oxygen-containing alicyclic heterocyclic groups include morpholino groups. Examples of the nitrogen- and sulfur-containing alicyclic heterocyclic group include a thiomorpholino group.Furthermore, examples of the alicyclic heterocyclic group include those in which one or more hydrogen atoms of the alicyclic heterocyclic group are replaced with a halogen atom, a hydroxyl group, or a linear, branched, or cyclic saturated aliphatic hydrocarbon group.Here, examples of the halogen atom or linear, branched, or cyclic saturated aliphatic hydrocarbon group that replaces the hydrogen atom include the same as those exemplified in the above cycloalkyl group.

[0035] The alicyclic heterocyclic group is preferably a monocyclic group. The alicyclic heterocyclic group preferably has 3 to 10 atoms constituting the ring, more preferably 3 to 8 atoms, and even more preferably 3 to 6 atoms.

[0036] More specifically, the alicyclic heterocyclic group for R is preferably a 2-pyrrolidinyl group, a 3-pyrrolidinyl group, a 2-tetrahydrofuranyl group, or a 3-tetrahydrofuranyl group.

[0037] The aromatic hydrocarbon group in R, which may have a substituent, may be either monocyclic or polycyclic.

[0038] Examples of the aromatic hydrocarbon group include a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an anthracenyl group, an azulenyl group, a heptalenyl group, and an octalenyl group, and further include those in which one or more hydrogen atoms of these aromatic hydrocarbon groups are substituted with a halogen atom, a hydroxyl group, or a linear, branched, or cyclic saturated aliphatic hydrocarbon group. Here, examples of the halogen atom or linear, branched, or cyclic saturated aliphatic hydrocarbon group that substitutes a hydrogen atom include the same as those exemplified in the above cycloalkyl group.

[0039] The aromatic hydrocarbon group is preferably monocyclic and has preferably 6 to 14 carbon atoms, more preferably 6 to 12 carbon atoms, and even more preferably 6 to 10 carbon atoms.

[0040] More specifically, the aromatic hydrocarbon group in R is preferably a phenyl group, a 2-methylphenyl group, a 3-methylphenyl group, a 4-methylphenyl group, a 2,3-dimethylphenyl group, a 3,4-dimethylphenyl group, a 2,4-dimethylphenyl group, a 2,4,6-trimethylphenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 4-fluorophenyl group, a 2,4-difluorophenyl group, a 3,5-difluorophenyl group, a 2-(trifluoromethyl)phenyl group, a 3-(trifluoromethyl)phenyl group, a 4-(trifluoromethylphenyl group), a 2-chlorophenyl group, a 3-chlorophenyl group, a 4-chlorophenyl group, or a 2,4-dichlorophenyl group.

[0041] The aromatic heterocyclic group in R is composed of carbon and other elements (for example, nitrogen, oxygen, sulfur, etc.) The aromatic heterocyclic group may be either monocyclic or polycyclic.

[0042] Examples of the aromatic heterocyclic group include a nitrogen-containing aromatic heterocyclic group, an oxygen-containing aromatic heterocyclic group, a sulfur-containing aromatic heterocyclic group, a nitrogen- and oxygen-containing aromatic heterocyclic group, a nitrogen- and sulfur-containing aromatic heterocyclic group, and an oxygen- and sulfur-containing aromatic heterocyclic group. Examples of the nitrogen-containing aromatic heterocyclic group include pyrrolyl group, imidazolyl group, pyrazolyl group, pyrazyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, indolizinyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinozinyl group, quinolyl group, isoquinolyl group, naphthyridinyl group, phthalazinyl group, quinoxalinyl group, quinazolinyl group, cinnolinyl group, pteridinyl group, carbazolyl group, β-carbolinyl group, phenanthridinyl group, acridinyl group, perimidinyl group, phenanthrolinyl group, phenazinyl group, and anthyridinyl group. Examples of the oxygen-containing aromatic heterocyclic group include furanyl group (furyl group), pyranyl group, benzofuranyl group, isobenzofuranyl group, chromenyl group, isochromenyl group, and xanthenyl group. Examples of sulfur-containing aromatic heterocyclic groups include thienyl, thiopyranyl, thiochromenyl, isothiochromenyl, thioxanthenyl, isothioxanthenyl, and thianthrenyl groups. Examples of nitrogen- and oxygen-containing aromatic heterocyclic groups include oxazolyl, isoxazolyl, furazanyl, and phenoxazinyl groups. Examples of nitrogen- and sulfur-containing aromatic heterocyclic groups include thiazolyl, isothiazolyl, and phenothiazinyl groups. Examples of oxygen- and sulfur-containing aromatic heterocyclic groups include phenoxathiinyl groups. Furthermore, examples of these aromatic heterocyclic groups in which one or more hydrogen atoms are substituted with halogen atoms, hydroxyl groups, or linear, branched, or cyclic saturated aliphatic hydrocarbon groups are given. Here, examples of the halogen atoms or linear, branched, or cyclic saturated aliphatic hydrocarbon groups that substitute for hydrogen atoms include the same as those exemplified in the above cycloalkyl groups.

[0043] The aromatic heterocyclic group is preferably monocyclic. The aromatic heterocyclic group preferably has 5 to 14 carbon atoms, more preferably 5 to 12 carbon atoms, and even more preferably 5 to 10 carbon atoms.

[0044] More specifically, the aromatic heterocyclic group in R is preferably a 2-pyrrolyl group, a 3-pyrrolyl group, a 2-furanyl group, or a 3-furanyl group.

[0045] Preferred examples of compound (1) in which R is a saturated aliphatic hydrocarbon group having 1 to 10 carbon atoms and which may have a substituent include the compounds shown below. It should be noted that these compounds are merely examples of preferred compound (1), and preferred compound (1) is not limited to these.

[0046] [ka]

[0047] Preferred examples of compound (1) in which R is an optionally substituted alicyclic heterocyclic group include the compounds shown below. It should be noted that these compounds are merely examples of preferred compound (1), and preferred compound (1) is not limited to these.

[0048] [ka]

[0049] Preferred examples of compound (1) in which R is an aromatic hydrocarbon group which may have a substituent include the compounds shown below. It should be noted that these compounds are merely examples of preferred compound (1), and preferred compound (1) is not limited to these.

[0050] [ka]

[0051] Preferred examples of compound (1) in which R is an aromatic heterocyclic group having 1 to 10 carbon atoms and which may have a substituent include the compounds shown below. It should be noted that these compounds are merely examples of preferred compound (1), and preferred compound (1) is not limited to these.

[0052] [ka]

[0053] The prophylactic or therapeutic agent for hydrocephalus of this embodiment may contain a pharma- ceutically acceptable salt of compound (1).

[0054] The term "pharmaceutical acceptable salt" as used herein refers to a non-toxic salt of compound (1), which can generally be prepared by reacting the free acid with an appropriate organic or inorganic base. Examples of salt forms of compound (1) include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolyl arsenate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthalene, iodide, isothionate, lactate, and the like. Salts include, but are not limited to, methyl phosphate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyl bromide, methyl nitrate, methyl sulfate, mucate, napsylate, nitrate, oleate, oxalate, pamoate, palmitate, pantothenate, phosphate / diphosphate, polygalacturonate, potassium, salicylate, sodium, stearate, sabastate, succinate, tannate, tartrate, theoclate, tosylate, triethiodide, valerate, and mixtures thereof.

[0055] <Method for producing compound (1)> Compound (1) can be produced, for example, by condensing a sulfonyl chloride having a desired R with 2-amino-3-benzyloxypyridine using a known reaction. More specifically, the process is as follows.

[0056] Compound (1) can be produced, for example, by a production method including a step of reacting a compound represented by the following general formula (1a) (hereinafter sometimes abbreviated as "compound (1a)") with a compound represented by the following general formula (1b) (hereinafter sometimes abbreviated as "compound (1b)") to obtain compound (1) (hereinafter sometimes abbreviated as "compound (1) production step"). Each step will now be described in detail.

[0057] [ka]

[0058] (In the formula, R is the same as above.)

[0059] [Compound (1) manufacturing process] In the process for producing compound (1), compound (1a) is reacted with compound (1b) to obtain compound (1). The above reaction to obtain compound (1) is a known condensation reaction.

[0060] (Compound (1a)) Compound (1a) is a known compound. In compound (1a), when R is a linear or branched alkyl group having from 1 to 10 carbon atoms, it is preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, an n-pentyl group, an isopentyl group, or an n-hexyl group.

[0061] Furthermore, when R is a cycloalkyl group having 3 to 10 carbon atoms, it is preferably a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.

[0062] Furthermore, when R is an alicyclic heterocyclic group having from 3 to 10 carbon atoms which may have a substituent, it is preferably a 2-pyrrolidinyl group, a 3-pyrrolidinyl group, a 2-tetrahydrofuranyl group, or a 3-tetrahydrofuranyl group.

[0063] Furthermore, when R is an aromatic hydrocarbon group having 6 to 10 carbon atoms which may have a substituent, it is preferably a phenyl group, a 2-methylphenyl group, a 3-methylphenyl group, a 4-methylphenyl group, a 2,3-dimethylphenyl group, a 3,4-dimethylphenyl group, a 2,4-dimethylphenyl group, a 2,4,6-trimethylphenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 4-fluorophenyl group, a 2,4-difluorophenyl group, a 3,5-difluorophenyl group, a 2-(trifluoromethyl)phenyl group, a 3-(trifluoromethyl)phenyl group, a 4-(trifluoromethylphenyl group), a 2-chlorophenyl group, a 3-chlorophenyl group, a 4-chlorophenyl group, or a 2,4-dichlorophenyl group.

[0064] Furthermore, when R is an aromatic heterocyclic group having from 5 to 10 carbon atoms which may have a substituent, it is preferably a 2-pyrrolyl group, a 3-pyrrolyl group, a 2-furanyl group or a 3-furanyl group.

[0065] (Compound (1b)) Compound (1b) is a known compound (2-amino-3-benzyloxypyridine). Compound (1b) may be synthesized by a known method, or a commercially available compound may be used.

[0066] (Reaction conditions) In the process for producing compound (1), it is preferable to use, as a reaction solvent, an appropriate organic solvent or an aqueous solvent such as a mixed solvent of the above organic solvent and water. Examples of organic solvents that can be used in the production process of compound (1) include, but are not limited to, dichloromethane, chloroform, toluene, trifluoromethylbenzene, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, and methyl tert-butyl ether. The solvents may be used alone or in combination of two or more kinds. When two or more kinds are used in combination, the combination and ratio thereof can be selected arbitrarily.

[0067] In the production process of compound (1), the amount of compound (1a) used is, for example, preferably 0.5 to 2 times the molar amount of compound (1b) used, and more preferably 1 to 1.5 times the molar amount.

[0068] In the process for producing compound (1), it is preferable to further carry out the reaction using a base. The base may be an organic base, an inorganic base, or an organic metal salt. Examples of the organic base include pyridine, 2,6-lutidine, 2,6-bis(tert-butyl)pyridine, triethylamine, dimethylisopropylamine, and N-methylmorpholine. Examples of the inorganic base include sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, and sodium amide. Examples of the organic metal salt include lithium diisopropylamide and butyl lithium. The bases may be used alone or in combination of two or more kinds. When two or more kinds are used in combination, the combination and ratio thereof can be selected arbitrarily. In the production process of compound (1), the amount of the base used is, for example, preferably 1 to 5 times the molar amount, and more preferably 2 to 4 times the molar amount, of the compound (1b) used.

[0069] In the process for producing compound (1), the reaction temperature is, for example, preferably 15°C or higher and 40°C or lower, and more preferably 20°C or higher and 30°C or lower. In the process for producing compound (1), the reaction time is, for example, preferably from 48 hours to 96 hours, and more preferably from 60 hours to 84 hours.

[0070] In the process for producing compound (1), the reaction is preferably carried out under an inert gas atmosphere. Examples of the inert gas include argon gas, helium gas, and nitrogen gas.

[0071] In the process for producing compound (1), after the reaction is completed, post-treatment may be carried out as necessary by a known method to extract compound (1). That is, post-treatment operations such as filtration, washing, extraction, pH adjustment, dehydration, and concentration may be carried out individually or in combination of two or more as appropriate, and compound (1) may be extracted by concentration, crystallization, reprecipitation, column chromatography, etc. Furthermore, the extracted compound (1) may be further purified as necessary by carrying out operations such as crystallization, reprecipitation, column chromatography, extraction, stirring and washing of crystals with a solvent individually or in combination of two or more as necessary once or more.

[0072] The structure of each compound such as compound (1), compound (1a), compound (1b), etc. can be confirmed by known techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and infrared spectroscopy (IR).

[0073] <Pharmaceutical composition for preventing or treating hydrocephalus> The pharmaceutical composition for preventing or treating hydrocephalus according to this embodiment (hereinafter sometimes simply referred to as "the pharmaceutical composition of this embodiment") contains the above-mentioned drug for preventing or treating hydrocephalus and a pharma- ceutical acceptable carrier. By administering the pharmaceutical composition of this embodiment, the symptoms of hydrocephalus can be improved.

[0074] The pharmaceutical composition of the present embodiment may be in a dosage form for oral use or a dosage form for parenteral use, but is preferably in a dosage form for parenteral use.Drug forms for oral use include, for example, tablets, capsules, elixirs, microcapsules, etc.Drug forms for parenteral use include, for example, injections, ointments, patches, etc.

[0075] As the pharmaceutically acceptable carrier, those generally used in the preparation of pharmaceutical compositions can be used without any particular limitation. More specifically, for example, binders such as gelatin, corn starch, gum tragacanth, gum arabic, etc.; excipients such as starch and crystalline cellulose, swelling agents such as alginic acid, solvents for injections such as water, ethanol, glycerin, etc.; adhesives such as rubber-based adhesives and silicone-based adhesives, etc. can be mentioned.

[0076] The pharmaceutical composition may contain additives, such as lubricants such as calcium stearate and magnesium stearate, sweeteners such as sucrose, lactose, saccharin and maltitol, flavorings such as peppermint and saffron oil, stabilizers such as benzyl alcohol and phenol, buffers such as phosphates and sodium acetate, solubilizers such as benzyl benzoate and benzyl alcohol, antioxidants, and preservatives.

[0077] The pharmaceutical composition can be formulated by appropriately combining the above-mentioned prophylactic or therapeutic agent for hydrocephalus with the above-mentioned pharma- ceutical acceptable carriers and additives, and mixing them in a unit dosage form required for generally accepted pharmaceutical practice.

[0078] The pharmaceutical composition may be used in combination with a therapeutic agent for another disease. For example, by using the above-mentioned prophylactic or therapeutic agent for hydrocephalus in combination with a therapeutic agent for dementia, it is possible to prevent or treat dementia while improving the symptoms of hydrocephalus. The above-mentioned prophylactic or therapeutic agent for hydrocephalus and the other drug may be in the same formulation or in separate formulations. Moreover, each formulation may be administered by the same administration route or by separate administration routes. Furthermore, each formulation may be administered simultaneously, sequentially, or separately with a certain time or period between them. In one embodiment, the above-mentioned prophylactic or therapeutic agent for hydrocephalus and the other drug may be in the form of a kit including them.

[0079] <Administration Method> Subjects to which the antibody is administered include, but are not limited to, humans, monkeys, dogs, cows, horses, sheep, pigs, rabbits, mice, rats, guinea pigs, hamsters, and cells thereof. Among these, mammals or mammalian cells are preferred, and humans or human cells are particularly preferred.

[0080] Administration to a patient can be performed by methods known to those skilled in the art, such as intrathecal injection, intraarterial injection, intravenous injection, subcutaneous injection, intranasal injection, transbronchial injection, intramuscular injection, transdermal injection, or oral injection. The dosage varies depending on the patient's weight and age, symptoms of the patient, administration method, etc., but a person skilled in the art can appropriately select an appropriate dosage.

[0081] The dosage of the pharmaceutical composition is considered to be, in terms of the amount of compound (1) or a pharma- ceutically acceptable salt thereof, in the case of oral administration, generally for an adult (body weight 60 kg), about 0.1 g to 4 g, preferably about 0.5 g to 2 g, more preferably about 1.0 g to 1.5 g, administered once a day or in divided doses.

[0082] When administered parenterally, for example, in the form of an injection, it is generally considered appropriate to administer to an adult (body weight 60 kg) approximately 0.05 g to 3 g, preferably approximately 0.3 g to 2 g, and more preferably approximately 0.5 g to 1.5 g per day, either once a day or in divided doses.

[0083] <Other embodiments> In one embodiment, the present invention provides a method for preventing or treating hydrocephalus, comprising administering to a patient in need of treatment an effective amount of a drug for preventing or treating hydrocephalus. Here, examples of the drug for preventing or treating hydrocephalus include those similar to those described above. Examples of hydrocephalus include those similar to those described above.

[0084] In one embodiment, the present invention provides a prophylactic or therapeutic agent for preventing or treating hydrocephalus. Here, examples of the prophylactic or therapeutic agent for hydrocephalus include those similar to those described above. Examples of hydrocephalus include those similar to those described above.

[0085] In one embodiment, the present invention provides use of a prophylactic or therapeutic agent for hydrocephalus for the manufacture of a prophylactic or therapeutic agent for hydrocephalus. Here, examples of the prophylactic or therapeutic agent for hydrocephalus include those similar to those described above. Examples of hydrocephalus include those similar to those described above. EXAMPLES

[0086] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.

[0087] [Example 1] (Test to confirm the effectiveness of TGN-073 in improving hydrocephalus using a mouse model of hydrocephalus 1) 1. Synthesis of TGN-073 TGN-073 was synthesized according to a previous report (Patent Document 1). Specifically, 2-amino-3-benzyloxypyridine (1.50 g, 7.50 mmol) was first added to a 50 mL round-bottom flask containing dried dichloromethane (35 mL). Then, an aqueous solution of 2,6-lutidine (2.62 mL, 22.5 mmol) was added to the stirred solution using a syringe, and the reaction vessel was filled with argon. Then, benzenesulfonyl chloride (1.05 mL, 8.25 mmol) was added to the stirred solution using a syringe. Then, the reaction was carried out under argon atmosphere at room temperature for 72 hours while stirring. Then, the obtained yellow solution was washed with 10% by mass of citric acid solution (2 x 25 mL) and saturated sodium carbonate solution (2 x 25 mL) based on the total mass of the solution. Then, the solution was dried using magnesium sulfate, filtered, and the water was evaporated to obtain dark red semi-solid crystals. The obtained dark red crystals were washed with hexane, and then eluted with a hexane solution containing 33% by mass of ethyl acetate based on the total mass of the solution through a flash chromatography column using silica gel (Wakogel 300), to obtain white crystals (hereinafter, sometimes referred to as "TGN-073") (yield: 0.309 g, yield: 13.5%).

[0088] High performance liquid chromatography (HPLC), high-resolution mass spectra (HR-MS), and 1 The results of the H-NMR analysis are shown below. HPLC: rt = 1.72 min (DAD), purity >95% (DAD, ELSD). HR-MS: anal calc'd for C 18 H 17 N2O3S + (M+H + ), 341.0955; found, 341.0932 (9.4 ppm). 1H NMR: δ5.14 ppm, s, 2H; 6.90 ppm, br-t, 1H; 7.29-7.41 ppm, m, 4H; 7.47-7.64 ppm, m, 6H; 7.96 ppm, br-d, J = 6.6 Hz, 2H.

[0089] [ka]

[0090] 2. Administration of TGN-073 to hydrocephalus model mice According to a previous report, hydrocephalus was induced by injecting 2.5 mg of kaolin into the cerebral cisterna of a mouse (2 months old) weighing approximately 30 g. Then, 30 minutes before and after the induction of hydrocephalus, 0.2 mL of saline in which TGN-073 was dissolved was intraperitoneally administered to give a concentration of 200 mg / kg of mouse body weight (hereinafter abbreviated as "200 mg / kg"). Furthermore, 200 mg / kg of TGN-073 was continuously administered for 72 hours using an osmotic pump (Alzet 1003D, flow rate: 1 μL / hour) implanted subcutaneously (total dose of TGN-073: 344 mg / kg). The control group was administered the same amount of saline (Saline) using the same protocol.

[0091] 3. Assessment of neurological signs After 72 hours, neurological symptoms were evaluated using a neurological score according to the following criteria. The results are shown in FIG.

[0092] (Evaluation Criteria) 1 point: Does not fall over even when pressed lightly 2 points: Unsteady, falls over when pushed 3 points: Gait disturbance, rolling movements 4 points: no spontaneous movement or immobility

[0093] As shown in FIG. 1, neurological symptoms were alleviated in the TGN-073-administered group compared with the saline-administered group (in FIG. 1, *: p<0.05, Mann-Whitney U Test).

[0094] 4. Magnetic resonance imaging (MRI) of H2 in mouse brain 17 O dynamics Next, 20%H2 17 0.2 mL of normal saline containing O was administered at a rate of 0.04 mL / sec using an autoinjector via a PE10 tube inserted into the right femoral vein of the TGN-073 and saline groups. Preclinical high-field magnetic resonance imaging (MRI) was then used to assess the H2+ concentration in the brain of each group of mice. 17 The dynamics of O were recorded at 8-second intervals for up to 70 minutes after administration. Based on the images obtained, the ventricular and cerebral edema area volumes, cortical cerebral blood flow, white matter edema, and neuronal density were measured.

[0095] T2-weighted MRI images of each mouse group are shown in Figure 2. Measurement results of the ventricle and cerebral edema area volume for each mouse group are shown in Figure 3. The TGN-073-administered group showed a reduction in the ventricle and cerebral edema area volume compared to the saline-administered group (Figure 3, **: p<0.01, T-test).

[0096] The results of measuring the cerebral blood flow in the cortex in each mouse group are shown in Figure 4. The TGN-073 administration group showed an improvement in the decrease in cerebral blood flow in the cortex compared to the saline administration group (Figure 4, *: p<0.05, T-test).

[0097] The results of measuring cerebral edema in the white matter of each mouse group are shown in Figure 5. Improvement in cerebral edema in the white matter was observed in the TGN-073-administered group compared to the saline-administered group (Figure 5, **: p<0.001, T-test).

[0098] The results of measuring neuronal density in the cortex of each mouse group are shown in Figure 6A, and the results of measuring neuronal density in the white matter of each mouse group are shown in Figure 6B. The decrease in neuronal density was suppressed in the TGN-073-treated group compared to the saline-treated group (Figure 6A, **: 0.01; Figure 6B, ***: p<0.001; both were T-tested).

[0099] These findings suggest that systemic administration of TGN-073 can control intracerebral water dynamics and improve hydrocephalus. As TGN-073 has been shown to reach the brain not only by injection but also by oral administration, oral administration may also be effective in chronic conditions.

[0100] [Example 2] (Confirmation test of TGN-073's effect on improving hydrocephalus using a mouse model of hydrocephalus 2) 1. Administration of TGN-073 to hydrocephalus model mice A TGN-073 administration group and a control group (saline administration group) were prepared using a method similar to that described in "2." of Example 1.

[0101] 2. Magnetic resonance imaging (MRI) study of the dynamics of MRI contrast agents in mouse brains Saline containing gadopentetate dimeglumine (GD) (2 mg / kg) as an MRI contrast agent was administered to each mouse via a PE10 tube inserted into the right femoral vein at a rate of 4 mL / sec using an automatic injector. Subsequently, images of the dynamics of GD in the mouse brain (cortex and cerebrospinal fluid (CSF)) were recorded at 8-second intervals using MRI up to 120 minutes after administration. The results are shown in Figure 7A. Figure 7B is a graph showing the inflow and velocity of GD into the brain parenchyma, created based on the images in Figure 7A.

[0102] As shown in Figures 7A and 7B, the TGN-073-treated group promoted cerebral water clearance compared to the saline-treated group, as measured by the amount and rate of GD influx into the brain parenchyma as markers.

[0103] [Example 3] (Test to confirm the effectiveness of TGN-073 in improving hydrocephalus using a mouse model of hydrocephalus 3) 1. Administration of TGN-073 to hydrocephalus model mice A TGN-073 administration group and a control group (saline administration group) were prepared using a method similar to that described in "2." of Example 1.

[0104] 2. Free water content in mouse brain using magnetic resonance imaging (MRI) Using preclinical high-field magnetic resonance imaging (MRI), we captured diffusion-weighted images of the free water content in the mouse brain 72 hours after hydrocephalus induction under 107 different measurement conditions, and calculated the free water content in the brain from these images. The results are shown in Figure 8A (calculated images of the free water content in each mouse group) and Figure 8B (measurement results of the amount of free water in the cerebral white matter).

[0105] As shown in Figures 8A and 8B, the TGN-073 administration group suppressed the increase in free water compared to the saline administration group. [Industrial Applicability]

[0106] According to the preventive or therapeutic drug for hydrocephalus and the pharmaceutical composition for the prevention or treatment of hydrocephalus of this embodiment, the symptoms of hydrocephalus can be improved, and it is useful for medical radical treatment.

Claims

1. A preventive or therapeutic drug for normal pressure hydrocephalus, comprising a compound represented by the following general formula (1) or a pharma- ceutical acceptable salt thereof as an active ingredient: 【Chemistry 1】 (In the formula, R is an aromatic hydrocarbon group which may have a substituent.)

2. The preventive or therapeutic drug for normal pressure hydrocephalus according to claim 1, wherein R is a phenyl group or a 4-chlorophenyl group.

3. The preventive or therapeutic drug for normal pressure hydrocephalus according to claim 1 or 2, which is administered orally in an amount of 0.1 g to 4 g per day to adults, or parenterally in an amount of 0.05 g to 3 g per day.

4. A pharmaceutical composition for preventing or treating normal hydrocephalus, comprising the agent for preventing or treating normal hydrocephalus according to any one of claims 1 to 3 and a pharma- ceutical acceptable carrier.

Citation Information

Patent Citations

  • Methods to reduce intracranial pressure

    JP2010533655A

  • Aquaporin 4 function promoter and pharmaceutical composition for neurological disorders

    WO2017150704A1